Document Type : Mini Review
Authors
1
Department of Cellular and Molecular Biology-Microbiology, faculty of advanced science and Technology, Tehran Medical science Islamic Azad University, Tehran, Iran.
2
Department of Microbial Biotechnology, faculty of advanced science and Technology, Tehran Medical science Islamic Azad University, Tehran, Iran.
3
Department of Molecular Cell Biology and Genetics, Bushehr Branch, Islamic Azad University, Bushehr, Iran
4
Department of Microbiology, faculty of advanced science and Technology, Tehran Medical science Islamic Azad University, Tehran, Iran.
10.30491/ijtmgh.2023.391295.1357
Abstract
Varicella Zoster Virus (VZV) is an alpha herpes virus that can conceal itself and produce shingles in addition to generating chicken pox. Varicella is a highly contagious illness brought on by vesicular skin sores, contamination, and maybe to a lesser extent, the propagation of the aerosolized virus. In comparison to children, adults with varicella had a much higher rate of primary VZV infection death. Different nations produce the varicella vaccines known as (Varivax; ProQuad; Merck & Co.), (Varilrix; Priorix-tetra; GSK), (Okavax; Biken, by Sanofi Pasteur), and (SuduVax; Green Cross). The amount of HDC passes, specific antibiotics included to assure sterility, stabilizers, and other minor components vary between different vaccines. The spread of the virus can be decreased dramatically by the widespread use of the varicella vaccine, particularly in a worldwide vaccination program. The World Health Organization suggested varicella vaccination in 1998 for nations where the illness poses a serious threat to public health. Nevertheless, many nations delayed the introduction of the universal varicella vaccine due to worries about the disease spreading to older populations, an increase in elderly herpes zoster, and cost-effectiveness. The purpose of the current research is to review varicella vaccination programs and their global effect.
Keywords
)
